Determination of Regulatory Review Period for Purposes of Patent Extension; DELSTRIGO-New Drug Application 210807

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for DELSTRIGO's new drug application (NDA 210807) due to a patent extension request submitted to the U.S. Patent and Trademark Office (USPTO).